The systemic inflammatory response in heart failure

被引:4
作者
Anderson, MR [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Rainbow Babies & Childrens Hosp, Dept Pediat,Div Pediat Pharmacol & Crit Care, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
pediatric heart failure; cytokines; inflammation; NF-kappa B; nitric oxide; tumor necrosis factor; systemic inflammatory response syndrome;
D O I
10.1016/S1058-9813(00)00053-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The physiologic diagnosis of heart failure has changed very little over the past several decades: heart failure is the inability of the cardiac output to meet the metabolic demands of the organism. The clinical definition of heart failure (also relatively unchanged) describes it as ventricular dysfunction that is accompanied by reduced exercise tolerance. Our understanding of the true pathophysiologic processes involved in heart failure have, however, changed. We have moved from thinking of heart failure as primarily a circulatory phenomenon to seeing it as a pathophysiologic state under the control of multiple complex systems. Over the past several years the dramatic explosion of research in the fields of immunology and immunopathology have added an additional piece to the puzzle that defines heart failure and have lead to an understanding of heart failure, at least in some part, as an 'inflammatory disease'. In this review we will examine several of the key inflammatory mediators as they relate to heart failure while at the same time attempting to define the source(s) of these mediators. We will examine key elements of the inflammatory cascade as they relate to heart failure such as: cytokines, 'proximal mediators' (e.g. NF-kappa B), and distal mediators (e.g, nitric oxide). We will end with a discussion of the potential therapeutic role of anti-inflammatory strategies in the future treatment of heart failure. Also, throughout the: review we will examine the potential pitfalls encountered in applying bench discoveries to the bedside as have been learned in the field of septic shock research. (C) 2000 Elsevier Science ireland Ltd. All rights reserved.
引用
收藏
页码:219 / 230
页数:12
相关论文
共 45 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]   p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial [J].
Abraham, E ;
Glauser, MP ;
Butler, T ;
Garbino, J ;
Gelmont, D ;
Laterre, PF ;
Kudsk, K ;
Bruining, HA ;
Otto, C ;
Tobin, E ;
Zwingelstein, C ;
Lesslauer, W ;
Leighton, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19) :1531-1538
[3]   Advances in the therapy for sepsis in children [J].
Anderson, MR ;
Blumer, JL .
PEDIATRIC CLINICS OF NORTH AMERICA, 1997, 44 (01) :179-+
[4]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[5]  
Bergman MR, 1996, J PHARMACOL EXP THER, V279, P247
[7]   Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats [J].
Bozkurt, B ;
Kribbs, SB ;
Clubb, FJ ;
Michael, LH ;
Didenko, VV ;
Hornsby, PJ ;
Seta, Y ;
Oral, H ;
Spinale, FG ;
Mann, DL .
CIRCULATION, 1998, 97 (14) :1382-1391
[8]  
De Keulenaer GW, 1998, ACTA CARDIOL, V53, P131
[9]   Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart [J].
Drexler, H ;
Kästner, S ;
Strobel, A ;
Studer, R ;
Brodde, OE ;
Hasenfuss, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (04) :955-963
[10]   EFFECTS OF VESNARINONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH HEART-FAILURE [J].
FELDMAN, AM ;
BRISTOW, MR ;
PARMLEY, WW ;
CARSON, PE ;
PEPINE, CJ ;
GILBERT, EM ;
STROBECK, JE ;
HENDRIX, GH ;
POWERS, ER ;
BAIN, RP ;
WHITE, BG .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :149-155